U.S. markets close in 4 hours 34 minutes
  • S&P 500

    4,570.03
    +56.99 (+1.26%)
     
  • Dow 30

    34,597.33
    +575.29 (+1.69%)
     
  • Nasdaq

    15,332.07
    +78.02 (+0.51%)
     
  • Russell 2000

    2,182.10
    +34.68 (+1.62%)
     
  • Crude Oil

    66.86
    +1.29 (+1.97%)
     
  • Gold

    1,767.10
    -17.20 (-0.96%)
     
  • Silver

    22.37
    +0.03 (+0.14%)
     
  • EUR/USD

    1.1313
    -0.0009 (-0.08%)
     
  • 10-Yr Bond

    1.4430
    +0.0090 (+0.63%)
     
  • GBP/USD

    1.3312
    +0.0034 (+0.26%)
     
  • USD/JPY

    113.0570
    +0.2770 (+0.25%)
     
  • BTC-USD

    56,374.26
    -2,561.86 (-4.35%)
     
  • CMC Crypto 200

    1,438.68
    -0.20 (-0.01%)
     
  • FTSE 100

    7,142.16
    -26.52 (-0.37%)
     
  • Nikkei 225

    27,753.37
    -182.25 (-0.65%)
     

EBS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Emergent BioSolutions Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / April 30, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Emergent BioSolutions Inc. ("Emergent" or "the Company") (NYSE:EBS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Emergent securities between July 6, 2020 and March 31, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/ebs.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) Emergent BioSolution's Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (2) these longstanding contamination risks and quality control issues at Emergent BioSolution's facility led to a string of FDA citations; (3) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (4) as a result of the foregoing, defendants' public statements about Emergent BioSolution's ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/ebs or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Emergent you have until June 18, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/641809/EBS-Investor-Alert-Bronstein-Gewirtz-Grossman-LLC-Notifies-Emergent-BioSolutions-Inc-Investors-of-Class-Action-and-Encourages-Shareholders-to-Contact-the-Firm